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Abstract
Purpose: We aimed to assess suicidality risk amongst people who had had
anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis.
Method: All people with a definitive diagnosis of anti-NMDAR encephalitis in West
China Hospital between June 2012 and February 2017 were identified and their notes
were retrospectively reviewed. Demographic and clinical characteristics and risk
predictors for suicidality were summarized; those with suicidality were compared to
those without.
Result: Seventeen of 133 people (13%) presented suicidality symptoms: 7 (5%) with
suicidal ideation; 8 (6%) who attempted suicide; and 2 (1.5%) who completed suicide.
Median age was 27 (16-78) years, most were female (13 [76%]). Compared with
those with no suicidality, psychiatric symptoms as the initial symptoms were higher
in those who reported suicidality (p=0.039); insomnia, aggression, mania, depression
and delusion were also more common (P<0.05), but multivariate analysis did not
identify any independent predictor. Recurrence of encephalitis was higher in people
with suicidality than in those without (p=0.020). Other characteristics were not
significantly different in those who had suicidality and those who did not.
Conclusion: Suicidality is a common and potentially lethal risk for people with
anti-NMDAR encephalitis. Those presenting with psychiatric symptoms as the initial
symptom and with insomnia, aggression, mania, depression and delusion should be
carefully screen for suicidality.
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Introduction
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disease
caused by autoantibodies against the NR1 subunit of the NMDA receptor (1, 2). More
than 1,000 cases have been reported since the original diagnosis in 2007 (2,3).
Typical features include psychiatric symptoms, seizures, cognitive impairment,
speech impairment, movement disorders, autonomic instability, central
hypoventilation, and decreased consciousness (3-6). Psychiatric symptoms are the
most important and commonest symptom (3-6). Disorganization, delusions,
hallucinations, agitation, aggression and insomnia are common psychiatric symptoms
reported amongst those presenting with the condition (3, 4, 7). The symptoms are
often similar to those of schizophrenia and this may result in misdiagnosis. Suicidality
may be a complication of schizophrenia; in some series up to 40% of people with
schizophrenia attempted suicide (8-10).No studies, however, apart from some case
series, appear to focus on suicidality amongst survivors of anti-NMDAR encephalitis
(11-17). In view of the similarity in presentation, we attempted to characterize
suicidality in people who had had anti-NMDAR encephalitis, and summarize their
clinical characteristics, risk factors and potential predictors.
Materials and methods
Patients
People who were admitted to the wards of West China Hospital between June 2012
and February 2017 with a definitive diagnosis of anti-NMDAR encephalitis were
enrolled into this retrospective study based on an existing registry. Diagnosis was
based on clinical characteristics and confirmed by anti-NMDAR IgG antibody
screening in serum and cerebrospinal fluid (CSF). Serum and CSF samples of
suspected cases were simultaneously obtained and sent to Peking Union Medical
College Hospital, China, or Oumeng Biotechnology Corporation, Beijing, China, for
testing. Samples were assessed by indirect immunofluorescence using EU 90 cells;
the method was previously reported in detail (6,18). After diagnostic confirmation,
immunotherapy was started. Subjects were also enrolled into an anti-NMDAR
encephalitis registry after written informed consent was obtained from either the
patient or their families or representatives.
The registry and this study were approved by the Ethical Committee of West China
Hospital, Sichuan University (No.20110818).
Data extraction and management
People who developed suicidality were identified mainly through reviewing the
registry and evaluating inpatient and follow-up records. Demographics, clinical
manifestations, results of auxiliary examination, treatment strategies and treatment
outcomes were extracted. Clinical manifestations were divided into: psychiatric
symptoms; seizures; cognitive impairment; dyskinesias and movement disorders;
speech dysfunction; autonomic instability; central hypoventilation; and decreased
consciousness. Psychiatric symptoms included mainly disorganization, insomnia,
agitation, mania, aggression, hallucinations, depression, anxiety, delusions and
psychomotor inhibition. Mood was assessed by the Zung Depression Scale (ZDS) (19)
and anxiety by the Zung Anxiety Scale (ZAS) (20). Participants were considered to be
depressed if their ZDS score was ≥ 50, and anxious if their ZAS score was ≥ 45. EEG
results were considered abnormal if clear-cut epileptiform discharges or abnormal
slow waves were recorded. For this study, only encephalitis-induced abnormalities
were considered abnormal findings on MRI; other abnormalities were not recorded
as abnormal. CSF results were considered abnormal if the white blood cell (>5/mm3)
or/and protein (>0.45g/L) were elevated. A titer of anti-NMDAR antibody in CSF ≥ 
1:100 was defined as strongly positive. All individuals were also screened for an
underlying tumor by MRI, ultrasound examination, contrast-enhanced computed
tomography, and tumor markers. All were followed-up through telephone contact or
outpatient clinic visits after the first month and every 3 months after the initiation of
immunotherapy. Outcomes of treatment were evaluated at the final follow up using
the modified Rankin Scale (mRS). Good outcome was defined as mRS score 0-2 and
poor outcome as mRS score 3-6. Relapse of encephalitis was defined as new onset or
worsening of symptoms occurring after an initial improvement or stabilization of at
least 2 months (5).
Definition of suicidality
Suicidality was classified according to the degree of severity: “suicidal ideation,”
“attempted suicide,” and “completed suicide”. “Suicidal ideation” referred to
expression of the thought of killing oneself without any practical attempt.
“Attempted suicide” and “completed suicide” were regarded as suicidal behavior
where life-threatening behavior occurred with the intention of jeopardizing life.
Self-injurious behavior with unknown intent was not included in suicidal behavior
(21).
Statistical analysis
Statistical analyses were performed using SPSS version 21.0. Univariate analyses were
performed to compare gender, age, initial symptoms, psychiatric symptoms, other
symptomatic presentations, tumor findings, abnormal EEG results, abnormal MRI
results, abnormal CSF results, strongly positive NMDAR-Ab in the CSF, positive
NMDAR-Ab in the serum, treatment, duration of follow-up, treatment outcomes, and
rate of relapse between individuals with and without suicidality and between those
with suicidal ideation and with suicidal behavior. Age and duration of follow-up were
analyzed as continuous variables, while the remaining variables were analyzed as
categorical variables. Wilcoxon test was used for continuous variables. Fisher’s exact
test or the chi-squared test were used for other categorical variables. All predictive
factors identified by univariate analyses were included into a further multivariable
logistic regression model. A two-sided p-value of 0.05 or less was considered to be
statistically significant.
Results
General clinical characteristics of individuals who presented with suicidality
A total of 133 people were diagnosed with anti-NMDAR encephalitis during the
period of interest. Seventeen (13%) presented suicidality after the onset of
encephalitis; 7 (5%) had suicidal ideation, 8 (6%) attempted suicide and 2 (1.5%) who
completed suicide. A further five people with self-injurious behavior were not
included as the intention was not known; one of them later died due to multiple
organ dysfunction. The median time interval between the initial symptoms of
anti-NMDAR encephalitis and suicidality was 1 month (range, 2 days-24 months); 10
of 17 had suicidality prior to admission, 3 during hospitalization, 2 after discharge,
and 2 during relapse. The demographic and clinical characteristics of those with
suicidality are presented in table 1. Median age was 27 years (range, 16-78 years),
and 13 (76%) were female. Educational level among them included one with only
primary school education, 5 with middle school education, 3 with high school
education, and 8 with higher education.
Fourteen individuals (82%) presented with psychiatric symptoms as the initial
symptoms, while 2 presented with a seizure and one with speech dysfunction.
Detailed information regarding psychiatric symptoms experienced by each individual
is listed in Table 2. Two (12%) were found to have neoplasia (one ovarian teratoma
and one adrenal adenoma).
All 17 individuals with suicidality had positive NMDAR-Ab in the CSF, with 6/17
being strongly positive; only 8/17 had positive serum antibodies. Brain MRI was
abnormal in 3 individuals, including one who had a lesion near the left anterior horn
of the lateral ventricle. The other two individuals with abnormal MRIs had multifocal
lesions; one had involvement of the left pons, cerebral peduncle, thalamus, callosum,
frontal lobe, periventricular area, and bilateral internal capsules, while the other had
involvement of the bilateral frontal and parietal lobes, periventricular triangle, and
left anterior horn of the lateral ventricle. Abnormal EEG results were present in 13 of
16 patients (81%) who had results available. Eight had abnormal CSF results. The
median follow-up duration was 13.5 months (range, 1-48 months). Treatment
outcomes of those with suicidality at the end of follow-up were assessed; 12 (71%)
had a good outcome (mRS 0-2). Of those with good outcome, 6 (50%) made a full
recovery (mRS 0). Five (29%) had a poor outcome (mRS 3-6) and of those, 3 died. Of
the 16 individuals with follow-up of 2 months or more, 5 (31%) had a recurrence.
Comparisons between those with and without suicidality
We compared the 17 individuals who had suicidality with the 116 without suicidality
(table 3). Sixty-five (56%) without suicidality had psychiatric symptoms as their initial
symptoms; and this was significantly lower than those with suicidality (56% vs. 82%,
p=0.039). Psychiatric symptoms in those with suicidality were also different from
those without. Univariable analysis showed that the proportion with delusion, mania,
insomnia, aggression, and depression were higher in those with suicidality than
those without suicidality (table 3). Multivariable logistic regression analysis, however,
did not identify independent predictors of suicidality (table 4). There were no
significant differences among other psychiatric symptoms (including disorganization,
anxiety, agitation, hallucination and psychomotor inhibition). There were no
significant differences between the two groups with regards to gender, age,
educational background, duration of follow-up, other clinical symptoms and auxiliary
examination results (table 3). There were no significant differences in treatment
outcomes at final follow-up between the two groups, but those with suicidality had a
higher rate of recurrence than those without suicidality (31% vs. 8%, p=0.020).
Comparisons between those with suicidal ideation and those with suicidal behavior
Detailed information comparing results for those with suicidal ideation only and
those with attempted suicide or who completed suicide is presented in Figure 1. The
proportion of people with abnormal CSF results was higher in those with suicidal
behavior than in those with suicidal ideation (70% vs. 14%, p=0.050). Gender, clinical
manifestations, psychiatric symptoms, tumor findings, auxiliary examination results,
treatment outcomes, and recurrence rates were not significantly different between
these two groups.
Discussion
This study focusing on suicidality in people with anti-NMDAR encephalitis found that
suicidality is not rare and was seen in over 10% of individuals, with 1.5% eventually
committing suicide. This is a higher suicide rate than suggested by the Chinese
national disease surveillance system which provided annual figures between
7.72/100,000 and 7.69/100,000 for completed suicide rate in the general population
around the time of the study (21). This increase had already been reported in a small
case series in which 3 of 12 people with anti-NMDAR encephalitis had suicidality (one
with suicidal ideation and two with suicide attempts) (23). Another study of the
NMDAR, NMDAR sub-unit mRNAs, and post-synaptic density protein 95 (PSD 95) in
postmortem brain tissue demonstrated that NMDAR sub-unit mRNAs levels and PSD
95 levels in people with suicidality were different from the control group (24).
Another study suggested that the levels of NMDAR antagonists and agonists were
also related to suicidality (21). Suicidality should, therefore, be seen not as rare, but
as a common and potentially serious manifestation of anti-NMDAR encephalitis. The
specific mechanism, however, warrants further study.
The demographic characteristics of those with suicidality suggested that it can
affect individuals of different ages, and educational backgrounds. It can also present
in different stages of encephalitis, from prior to admission, to after discharge and
also during recurrence. One of the affected committed suicide eight months post
discharge after suffering from suspected depression for about one month. In this
particular individual, follow up prior to the onset of depression had noted full clinical
recovery. It is possible that, as there was full recovery of consciousness, speech
function, cognitive abilities, and other psychiatric symptoms, mood was overlooked
and an evaluation of suicidality risk was not performed. Two further individuals had
suicidal ideation or attempted suicide post discharge. Assessing the risk of suicidality
is essential during telephone and outpatient clinic visits, even in those who appear to
have had a good recovery.
We also analyzed clinical manifestations. Our cases presented with a variety of
clinical symptoms (Table 1). Of interest is that those whose initial presentation
included florid psychiatric symptoms were more likely to have suicidality than those
who didn’t present with psychiatric symptoms. Psychiatric symptoms were also
different between the two groups on univariable analysis throughout the course of
the disease. Insomnia, aggression, mania, depression, and delusions were more
common in those with suicidality (p<0.05). These findings are also consistent with
previous studies of risk factors for suicidal behavior in other mental disorders
(25-29).More attention should be paid to people with anti-NMDAR encephalitis with
florid psychiatric symptoms, and assessment of the risk of suicidal behavior should be
made. Multivariate analysis, however, did not identify independent predictors of
suicidality in this study. This could be due to the small sample size and further studies
with larger samples are needed to identify the predictors of suicidality of people with
anti-NMDAR encephalitis.
Previous studies have shown that higher antibody titers were related to poorer
outcomes (30, 31). In this study, the preliminary analysis of those with strongly
positive antibodies in the CSF showed no significant difference between those with
and without suicidality (p=0.257) nor between those with suicidal ideation and those
with suicidal behavior (p=0.644). The MRI results of individuals with suicidality may
be normal, but may also show focal or multifocal lesions affecting limbic system,
frontal and parietal lobes, periventricular areas, internal capsule, callosum, pons,
cerebral peduncles, and thalamus. A previous study showed that some lesions, such
as smaller right parahippocampal cortex volume and superior temporal gyrus volume
could be related to suicidality (31). Due to small numbers and a relatively low rate of
abnormal MRI in anti-NMDAR encephalitis, we could not ascertain relationships
between suicidality and lesion location. Compared to individuals without suicidality,
no significant differences were found among MRI, EEG, and CSF results. Abnormal
CSF results were more common in those with suicidal behavior than in those with
only suicidal ideation (70% vs. 14%, p=0.05). Abnormal CSF results have also been
shown to be predictive of poor outcomes (3, 6). Other studies have also shown that
elevated levels of inflammatory factors in the CSF, such as interleukin-6, were related
to suicide attempts (33), and the abnormal CSF results were likely related to
inflammatory activation. People with abnormal CSF results warrant screening for
suicidality. Further studies are needed to identify potential biomarkers for suicidality
in people with anti-NMDAR encephalitis.
Treatment outcomes at last follow up were not significantly different between
those with and without suicidality. Interestingly, two individuals had suicidality
during a relapse but not during the first episode. Individuals with suicidality also had
a higher rate of recurrence of encephalitis (31% vs. 8%, p=0.020).We speculate,
therefore, that there may be a relationship between relapse and suicidality. Previous
reports suggest that symptomatology during relapse may be less severe than the first
episode (5).In those with recurrence, therefore, more attention should be paid to the
increased risk of suicidality, rather than to the less severe symptoms. Studies with
larger samples are needed to confirm these suggestions.
Our study has several limitations. Firstly, mainly due to study design bias and the
limitations inherent in uncontrolled retrospective research, we have not assessed
suicidality consistently throughout the study period, particularly in the earlier stages.
We have also not used a scale to estimate the severity of suicidality and this could
have led to inevitable recall bias although this may lead an underestimation of the
suicidality. Secondly, due to the small sample of people with suicidality comparative
results might be compromised. Lastly, the initial symptom was defined according to
the clinician’s expertise and the families’ descriptions, which might cause
interpretative bias, especially, when the initial symptom were not characteristic.
Conclusion
Our findings suggest that suicidality is a common, potentially lethal risk in people
with anti-NMDAR encephalitis which should not be ignored by clinicians. People
presenting with psychiatric symptoms such as insomnia, aggression, mania,
depression, or delusions at the initial and subsequent presentation may be at
particular risk. Our study, however has several limitations so our findings should be
interpreted with caution. Further prospective studies with larger sample sizes and
more precise classification of suicidality are urgently needed.
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Table 1. The demographic characteristics and clinical information of patients with suicidality
No./suicidal
classification
Sex/age
(year)
Educational
background
Initial symptom
IT from onset
to suicidality
Tumor Brain MRI EEG CSF NMDAR-Ab mRS
1a/SI F/25 Middle
school
Disorganization 14m (during
relapse)
No Normal Abnormal WBC <5/mm3
Pro <0.45g/L
CSF +
Serum +
6
2/SI F/38 Middle
school
Insomnia,
depression
1m (prior to
admission)
No Normal Normal WBC <5/mm3
Pro <0.45g/L
CSF +
Serum +
1e
3a/SI F/29 College Agitation,
insomnia,
depression
1m (prior to
admission)
No Abnormalb Normal WBC <5/mm3
Pro <0.45g/L
CSF +
Serum -
2f
4/SI F/52 Middle
school
Depression,
anxiety
1m (prior to
admission)
No Normal Normal WBC <5/mm3
Pro <0.45g/L
CSF +
Serum -
0
5/SI F/19 Middle
school
Seizure 3m (during
hospitalization)
No Normal Abnormal WBC <5/mm3
Pro <0.45g/L
CSF +
Serum -
0
6/SI M/27 High school Disorganization 20d (prior to
admission)
No Normal Abnormal WBC 12/mm3
Pro <0.45g/L
CSF +
Serum +
0
7/SI M/35 College Anxiety,
delusion
14d (during
hospitalization)
No Abnormalc Abnormal WBC <5/mm3
Pro <0.45g/L
CSF +
Serum -
0
8/AS F/24 College Speech
dysfunction
2m (prior to
admission)
No Normal Abnormal WBC 20/mm3
Pro <0.45g/L
CSF +
Serum +
1g
9a/AS F/25 High school Delusion,
hallucination
24m (prior to
admission)
No Normal Abnormal WBC 10/mm3
Pro <0.45g/L
CSF +
Serum -
1h
10/AS F/27 College Insomnia,
depression
5m (prior to
admission)
No Normal Normal WBC <5/mm3
Pro <0.45g/L
CSF +
Serum -
0
11/AS M/78 College Agitation, 2m (during Left Normal Abnormal WBC <5/mm3 CSF + 4i
Abbreviations: AS = attempted suicide; CS = completed suicide; CSF = cerebrospinal fluid; EEG = electroencephalogram; F=female; FLAIR = fluid attenuated inversion
recovery sequence; IT=interval time M=male; MRI = magnetic resonance imaging; mRS = modified Rankin Scale; NA = data not available; NMDAR-Ab =
N-methyl-D-aspartate receptor antibody; Pro = protein; SI = suicidal ideation; T2WI = T2-weighted Imaging; WBC = white blood cell.
a. Patients relapsed;
b. Lesions involving left pons, cerebral peduncle, thalamus, callosum, frontal, periventricular, and bilateral internal capsule with high signal on T2WI and FLAIR;
c. Lesion nearby left anterior horn of lateral ventricle with high signal on T2WI and FLAIR;
d. Lesions involving bilateral frontal, parietal, periventricular triangle, and nearby left anterior horn of lateral ventricle with high signal on T2WI and FLAIR;
Residual deficits are: e. Agitation, anterograde amnesia; f. Weakness and occasionally movement disorder of right limb; g. Agitation; h. Memory deterioration; i.
Cognitive impairment, weakness of limb, lack of self-care ability; j. Agitation; k. Anterograde amnesia; l. Insomnia, disorganization, agitation, aggression, mania,
anxiety, delusion, suicidal ideation.
disorganization hospitalization) adrenal
adenoma
Pro 0.48g/L Serum -
12/As F/28 College Delusion,
hallucination
2d (prior to
admission)
Right
ovarian
teratoma
Normal NA WBC 54/mm3
Pro <0.45g/L
CSF +
Serum +
1j
13/AS M/33 College Insomnia,
depression
7d (prior to
admission)
No Normal Abnormal WBC 50/mm3
Pro <0.45g/L
CSF +
Serum +
1k
14a/AS F/46 College Insomnia,
delusion
10d (prior to
admission)
No Normal Normal WBC 10/mm3
Pro <0.45g/L
CSF +
Serum -
4l
15/AS F/16 Middle
school
Seizure 1m (post
discharge)
No Normal Abnormal WBC <5/mm3
Pro <0.45g/L
CSF +
Serum -
0
16/CS F/27 High school Disorganization
, hallucination
9m (post
discharge)
No Abnormald Abnormal WBC 20/mm3
Pro 0.79g/L
CSF +
Serum +
6
17a/CS F/24 Primary
school
Insomnia,
anxiety
17m (during
relapse)
No Normal Abnormal WBC <5/mm3
Pro <0.45g/L
CSF +
Serum +
6
Table 2. Psychiatric symptoms of patients with suicidality
No.
Disorganization
(88%)
Agitation
(88%)
Insomnia
(82%)
Mania
(82%)
Depression
(65%)
Aggression
(59%)
Hallucination
(59%)
Anxiety
(53%)
Delusion
(53%)
Psychomotor
inhibition
(6%)
1 + + + + + - - + + -
2 + + + + + + - + - -
3 - + + + + + - - - -
4 + + + + + + + + + -
5 + + + + - + + - - -
6 + + - + - + - - - -
7 + + + + - + - + + -
8 + + + + - + + - + -
9 + + + + + + + + + -
10 + + + + + - + + - -
11 + - - - + - + - - -
12 - + - + - - + - + -
13 - - + - + - + - - -
14 + + + + + + + + + -
15 + + + + - - - - - -
16 + + + - + - - + + +
17 + + + + + + + + + -
Table 3. Comparisons between patients with and without suicidality
All n (%) Suicidality n (%) No suicidality n
(%)
P values
Total 133 17 116
Sex (female) 79 (59) 13 (76) 66 (57) 0.125a
Age, year, median (range) 25 (9-78) 27 (16-78) 24 (9-71) 0.071b
Education background
(college or above)
45 (34) 8 (47) 37 (32) 0.217a
Psychiatric symptoms as
initial symptom
79 (59) 14 (82) 65 (56) 0.039a
Psychiatric symptoms
Disorganization 113 (85) 15 (88) 98 (85) 1.000c
Agitation 109 (82) 15 (88) 94 (81) 0.737c
Insomnia 69 (52) 14 (82) 55 (47) 0.007a
Mania 68 (51) 14 (82) 54 (47) 0.006a
Depression 55 (41) 11 (65) 44 (38) 0.036a
Aggression 42 (32) 10 (59) 32 (28) 0.010a
Hallucination 54 (41) 10 (59) 44 (38) 0.101a
Anxiety 53 (40) 9 (53) 44 (38) 0.238a
Delusion 30 (23) 9 (53) 21 (18) 0.003c
Psychomotor inhibition 22 (17) 1 (6) 21 (18) 0.304c
Seizure 111 (84) 12 (71) 99 (85) 0.159c
Cognitive impairment 83 of 97 (86) 11 of 14 (79) 72 of 83 (87) 0.420c
Dyskinesias and movement
disorders
57 (43) 8 (47) 49 (42) 0.708a
Speech dysfunction 43 (32) 6 (35) 37 (32) 0.780a
Autonomic instability 39 (29) 5 (29) 34 (29) 1.000c
Decreased consciousness 81 (61) 7 (41) 74 (64) 0.074a
Central hypoventilation 29 (22) 3 (18) 26 (22) 1.000c
Tumor 23 (17) 2 (12) 21 (18) 0.736c
Abnormal EEG 97 of 116 (84) 13 of 16 (81) 84 of 100 (84) 0.725c
Abnormal MRI 49 of 127 (39) 3 of 17 (18) 46 of 110 (42) 0.057a
Abnormal CSF 86 (65) 8 (47) 78 (67) 0.104a
Strongly positive Ab in CSF 64 (48) 6 (35) 58 (50) 0.257a
Positive Ab in serum 79 (59) 8 (47) 71 (61) 0.267a
Treatment
IVIG 123 (92) 17 (100) 106 (91) 0.360c
MTP 69 (52) 8 (47) 61 (53) 0.670a
Duration of follow-up,
month, median (range)
15.0 (1-48) 13.5 (1-48) 15.0 (2-46) 0.512a
Good outcome 104 of 123 (85) 12 of 17 (71) 92 of 106 (87) 0.139c
Relapse 14 of 122 (11) 5 of 16 (31) 9 of 106 (8) 0.020c
Abbreviations: Ab = N-methyl-D-aspartate receptor antibody; CSF = cerebrospinal fluid; EEG =
electroencephalogram; IVIG = intravenous immunoglobulin; MTP = methylprednisolone; MRI =
magnetic resonance imaging.
a. Chi-squared test;
b. Wilcoxon test;
c. Fisher’s exact test.
Table 4. Multivariate analysis of factors associated with suicidality in people with anti-NMDAR
encephalitis.
Variables Adjusted odds ratio 95% CI P value
Psychiatric symptoms as
initial symptom
2.973 0.730-12.114 0.128
Aggression 1.409 0.356-5.576 0.625
Depression 1.137 0.310-4.176 0.847
Mania 3.273 0.626-17.119 0.160
Insomnia 2.841 0.663-12.164 0.159
Delusion 2.681 0.761-9.443 0.125
Abbreviations: CI = confidence interval.
Figure 1. Comparisons between people with suicidal ideation and those with suicidal behavior
The blue bar represents people with suicidal ideation, the red bar represents people with suicidal
behavior. *P value of 0.05 or less, Fisher’s exact test.
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